Wednesday, December 23, 2015 2:42:39 PM
BASKING RIDGE, N.J. (December 23, 2015) – Caladrius Biosciences, Inc. (“Caladrius” or the “Company”) (NASDAQ: CLBS), a cell therapy company combining an industry-leading development and manufacturing services provider with a therapeutic development pipeline, announces the appointment of Steven S. Meyers, previously the Board’s lead independent Director, as interim Chairman of the Board, subsequent to the resignation of Robin L. Smith, M.D, as Chairman of the Board and a Director. In addition, the Company announces the appointment of Robert A. Preti, Ph.D., Senior Vice President, Manufacturing and Technical Operations and Chief Technology Officer of Caladrius Biosciences, to its Board of Directors. With these changes, the Caladrius Biosciences Board remains at eight Directors.
“We are delighted to welcome Dr. Preti to the Board as we believe his in-depth knowledge of and experience with cell therapy development and manufacture will provide us with invaluable insight and guidance as we continue to build our PCT business as an important foundational asset and driver of future value for our Company,” stated David J. Mazzo, Ph.D., Chief Executive Officer of Caladrius Biosciences. “We thank Dr. Smith for her many years of service to the Company and its Board and wish her well in her future endeavors.”
Dr. Preti is the President and co-founder of PCT, a Caladrius company, and the visionary behind its successful growth and development strategy over much of the last two decades. As Chief Technology Officer of Caladrius he is involved in assessing and directing the development of Caladrius’ cell therapy pipeline, as well as participating in setting the Company’s strategic direction.
Dr. Preti built PCT to meet a recognized need for high quality manufacturing and development services in an emerging industry. As the cell therapy field has grown, so too has PCT— the company has now served over 120 clients and performed more than 20,000 cell therapy procedures. His leadership has been instrumental in creating PCT’s client-focused model that helps bridge the gap between discovery and patient care through efficient transfer of cell-based therapies from laboratory to clinical practice to commercialization.
Before assuming his role at PCT, Dr. Preti held a number of positions within the cellular therapy and blood banking fields. From 1996 to 1999, he was the director of hematopoietic stem cell processing and applied research at Hackensack University Medical Center in Hackensack, N.J. He served in several capacities with the New York Blood Center from 1990 to 1997, including tissue bank director, director of hematopoietic stem cell processing, scientific director and associate investigator. He also worked as a research scientist for Marrow-Tech Incorporated, which went on to become Advanced Tissue Sciences (ATIS), where work in his laboratory lead to the Dermagraft product currently marketed by Organogenesis.
In addition, Dr. Preti has served on the Stem Cell Banking Committee and Cord Blood Subcommittee of the New York State Department of Health and on the New Jersey State Department of Health’s Blood Bank Advisory Committee, chairing the Hematopoietic Progenitor Cell Processing Subcommittee. He has served in a leadership capacity for many professional organizations, including treasurer and founding member of the International Society of Hematotherapy and Graft Engineering, now called ISCT (International Society for Cellular Therapy). He has published and presented extensively on a variety of topics relating to cellular therapies. He recently completed a five year term as a director for AABB, and is currently Vice Chairman for the Alliance for Regenerative Medicine (ARM), where, among other activities, he co-chaired the Standards and Technology Committee.
Dr. Preti holds a Bachelor of Science degree in biology from Fordham University, and a Master of Science degree and Doctorate, both in biology, from New York University
Recent LSTA News
- Lisata Therapeutics and Qilu Pharmaceutical Announce First Patient Treated in Qilu’s Phase 2 Trial in China of LSTA1 in Patients with Metastatic Pancreatic Ductal Adenocarcinoma • GlobeNewswire Inc. • 04/23/2024 11:30:00 AM
- Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Osteosarcoma • GlobeNewswire Inc. • 04/09/2024 12:30:00 PM
- Lisata Therapeutics to Participate in Upcoming April 2024 Industry and Investor Events • GlobeNewswire Inc. • 04/03/2024 12:30:00 PM
- Lisata Therapeutics Announces U.S. FDA Rare Pediatric Disease Designation Granted to LSTA1 for the Treatment of Osteosarcoma • GlobeNewswire Inc. • 03/21/2024 12:00:00 PM
- Lisata Therapeutics to Present at the Life Science Investor Forum on March 7ᵗʰ • GlobeNewswire Inc. • 03/04/2024 01:00:00 PM
- Lisata Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/29/2024 09:05:00 PM
- Lisata Therapeutics to Host Year-End 2023 Conference Call on Thursday, February 29, 2024 at 4:30 p.m. Eastern Time • GlobeNewswire Inc. • 02/22/2024 01:00:00 PM
- Lisata Therapeutics to Present at BIO CEO & Investor Conference • GlobeNewswire Inc. • 02/20/2024 01:00:00 PM
- Lisata Therapeutics to Present at the Sequire Investor Summit in Puerto Rico • GlobeNewswire Inc. • 01/18/2024 01:30:00 PM
- Lisata Therapeutics Announces First Patient Treated in the Phase 2a Trial of LSTA1 in Patients with Glioblastoma Multiforme • GlobeNewswire Inc. • 01/17/2024 01:00:00 PM
- Lisata Therapeutics Announces Publication of Case Report on a Complete Response in a Metastatic Gastroesophageal Adenocarcinoma Patient Treated with LSTA1 in Combination with Standard-of-Care Therapy • GlobeNewswire Inc. • 01/04/2024 01:00:00 PM
- Lisata Therapeutics Announces Completion of Enrollment in Phase 2b ASCEND Trial of LSTA1 in Metastatic Pancreatic Ductal Adenocarcinoma • GlobeNewswire Inc. • 12/12/2023 01:00:00 PM
- Lisata Therapeutics to Present at NobleCon19 Investor Conference • GlobeNewswire Inc. • 11/28/2023 09:05:00 PM
- Lisata Therapeutics Announces Participation in Upcoming Conferences in November • GlobeNewswire Inc. • 11/09/2023 09:05:00 PM
- Lisata Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 11/02/2023 08:05:00 PM
- Lisata Therapeutics to Host Third Quarter 2023 Financial Results Conference Call on Thursday, November 2nd at 4:30 p.m. Eastern Time • GlobeNewswire Inc. • 10/26/2023 12:00:00 PM
- Lisata Therapeutics Announces First Patient Treated in the Cholangiocarcinoma Cohort of the BOLSTER Trial of LSTA1, a Novel Tumor-Targeting and Penetrating Peptide • GlobeNewswire Inc. • 10/24/2023 12:00:00 PM
- Lisata Therapeutics Announces European Medicines Agency Has Granted LSTA1 Orphan Drug Designation for the Treatment of Pancreatic Cancer • GlobeNewswire Inc. • 10/17/2023 12:00:00 PM
- Lisata Therapeutics Announces Participation in Upcoming Conferences in October • GlobeNewswire Inc. • 09/28/2023 12:00:00 PM
- Lisata Therapeutics Announces Participation in InfoSec World 2023 • GlobeNewswire Inc. • 09/20/2023 12:00:00 PM
- Lisata Therapeutics Announces First Patient Treated in the BOLSTER Trial of LSTA1, a Novel Tumor-Targeting and Penetrating Peptide, in Patients with Advanced Solid Tumors • GlobeNewswire Inc. • 09/12/2023 12:00:00 PM
- Lisata Therapeutics Announces Outcome of Interim Futility Analysis for its Phase 2b ASCEND Trial of LSTA1 in Metastatic Pancreatic Ductal Adenocarcinoma • GlobeNewswire Inc. • 09/06/2023 12:00:00 PM
- Lisata Therapeutics Announces Participation in Upcoming Conferences in September • GlobeNewswire Inc. • 09/05/2023 12:00:00 PM
- Impilo Therapeutics Launches to Enable Nucleic Acid-Based Medicines to Effectively Treat Solid Tumor Cancers • PR Newswire (US) • 08/15/2023 12:30:00 PM
- Lisata Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 08/14/2023 08:05:00 PM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM
Avant Technologies Launches Advanced AI Supercomputing Network and Expansive Data Solutions • AVAI • Apr 23, 2024 8:00 AM
BestGrowthStocks.com Issues Comprehensive Analysis of Triller Merger with AGBA Group Holding Limited • AGBA • Apr 22, 2024 1:00 PM
Cannabix Technologies to Present Marijuana Breathalyzer Technology at International Association for Chemical Testing (IACT) Conference in California • BLO • Apr 22, 2024 8:49 AM